Pharmaceuticals Export Business Master Report

You are about to know exactly what this business costs, where it pays, and what to do first.

Most people entering pharmaceutical export spend eighteen months and several lakh rupees learning what is in this document. India exported US$ 31.11 billion of pharmaceuticals in FY 2025-26 and supplies 47% of every generic prescription dispensed in the United States. The opportunity is not in question. What stops people is that nobody hands them the numbers, the sequence, or the honest timeline.

This report does.

What you walk away knowing

•    Should I pick this product? — a scored Go/No-Go decision framework across eight weighted factors

•    Which markets are actually good for me? — the top-10 destination analysis plus a market-by-market matrix of realised price against payment terms

•    What price and margin can I get? — indicative FOB and CIF price ladders by product form, and the full value-addition margin ladder from intermediate to biosimilar

•    What capital do I need to manufacture? — three CAPEX scenarios (Micro, Small/SME, Medium) built line by line from land and cleanrooms to HPLCs and validation

•    What are my fixed costs, variable costs and monthly operational costs? — fixed cost per month, variable cost per 1,000 tablets, and total monthly operating cost at 50%, 70% and 90% capacity utilisation, with break-even volume and value

•    Where do I procure as a merchant trader, and on what terms? — twelve named Indian sourcing clusters, a nine-step supplier qualification method, standard procurement terms and the clauses that must be in your purchase agreement

•    What payment terms will I actually get, and which market pays best? — a full comparison across twelve destination markets with payment risk ratings and a recommended entry sequence

•    What documents do I need in India, and in each destination? — the complete India-side compliance table and destination-side requirements for four priority markets

•    Which Export Promotion Council, and what incentives exist? — Pharmexcil in detail, plus RoDTEP, PLI for pharmaceuticals, PLI for bulk drugs, SPI, MAI, EPCG and state schemes

•    Where do I find buyers? — buyer personas by type plus thirteen named routes including the 2026 trade show calendar with exact dates and venues

•    How do I make this business a success? — nine decisions that determine whether it compounds or collapses

What is inside

Four complete business models covered end to end — Domestic, Manufacturing, Merchant Trading and Export — across 73 sections in 8 parts. Both operational flowcharts (Manufacturer Exporter and Merchant Exporter) are mapped stage by stage with decision points. Every data-heavy section is tabulated.

Current as at August 2026, including the US Section 232 proclamation of 2 April 2026, the phased generic tariff schedule announced on 21 July 2026 (0% to July 2028, then 100%, then 200%), revised Schedule M becoming binding on every Indian manufacturer from 1 January 2026, and the current RoDTEP notification position.

Who this is for

Existing formulation and API manufacturers with idle capacity · domestic pharma distributors moving into export · chemical and intermediates manufacturers integrating forward · pharmacists and healthcare professionals partnering with contract manufacturers · merchant traders and export houses adding a pharmaceutical line · anyone evaluating a pharmaceutical manufacturing plant in India.

Who this is not for

Anyone who needs revenue inside 90 days. This report tells you plainly that the first regulated-market shipment lands 8–20 months after you decide to start — and then tells you exactly how to fund and execute that runway.

Format and delivery

79-page book-format report, professionally designed and branded. Instant digital download after purchase.

Want this pressure-tested against your own capital and product?

Book a 60-minute 1:1 export business consultation with JB Experts leadership:

https://meeting.jbexperts.com/#/60min